Skip to main content
Premium Trial:

Request an Annual Quote

Eureka Genomics to Merge with Nanobac Pharma

NEW YORK (GenomeWeb News) – Eureka Genomics plans to merge with Nanobac Pharmaceuticals under a stock and cash deal, the bioinformatics company said today.

Under a memorandum of understanding, Eureka stockholders will receive new shares of Nanobac common stock and own 85 percent of the combined company, which will operate under the Eureka Genomics name. Nanobac has already provided Eureka with initial funds, and the deal is expected to close in the second quarter of 2009.

"We believe this merger is the right move for Nanobac and could lead to a significant increase in shareholder value," Nanobac Co-Chairman Benedict Maniscalco said in a statement.

Eureka CFO and COO Didier Perez called the merger "an important step in our R&D business development efforts," and said it should improve shareholder value for privately held Eureka as well.

Nanobac possesses a drug discovery program focused on inhibiting, destroying, or neutralizing calcifying nanoparticles. The company also has a diagnostic program through which it offers IVD kits and reagents for detecting CNPs, and it has a lab, Nanobac OY Clinical Laboratory, in Finland. The company also has a bioanalytical services business focused on detecting and eliminating CNP contamination from cell lines, animal and human derived materials, and diagnostic procedures.

Perez said the merger will advance Eureka's "next-generation functional genomics platform technology and bioinformatics analyses" that can help to "transform the development of highly valuable, cost-effective diagnostics, therapeutics, vaccines, and clean-tech products."

Nanobac had signed a deal a year ago to acquire DNAPrint Genomics, but that deal fell through after Nanobac was unable to raise additional funds before a deadline on March 31, 2008. DNAPrint Genomics has since closed its operations.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.